Zacks Research Estimates Amarin's Q2 Earnings (NASDAQ:AMRN)

Amarin Co. plc (NASDAQ:AMRN - Free Report) - Research analysts at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for shares of Amarin in a report released on Wednesday, May 28th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn ($0.87) per share for the quarter, up from their previous estimate of ($1.12). The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.81) EPS, FY2025 earnings at ($3.74) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($1.18) EPS, FY2026 earnings at ($3.21) EPS, Q1 2027 earnings at ($0.32) EPS and FY2027 earnings at ($2.52) EPS.

A number of other equities analysts also recently issued reports on AMRN. Wall Street Zen raised shares of Amarin from a "sell" rating to a "hold" rating in a research note on Thursday, May 8th. The Goldman Sachs Group dropped their target price on Amarin from $20.00 to $7.00 and set a "sell" rating on the stock in a report on Thursday, April 17th.

Amarin Trading Up 1.9%

Shares of AMRN stock traded up $0.22 during trading hours on Friday, reaching $11.81. The company's stock had a trading volume of 69,490 shares, compared to its average volume of 76,337. The stock has a market capitalization of $244.55 million, a P/E ratio of -130.83 and a beta of 0.66. Amarin has a one year low of $7.08 and a one year high of $17.58. The firm's fifty day simple moving average is $10.02 and its 200 day simple moving average is $10.22.

Amarin (NASDAQ:AMRN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Banque Cantonale Vaudoise bought a new position in Amarin in the first quarter valued at about $25,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Amarin during the fourth quarter worth about $36,000. Kornitzer Capital Management Inc. KS grew its position in shares of Amarin by 4.0% during the first quarter. Kornitzer Capital Management Inc. KS now owns 88,200 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 3,400 shares in the last quarter. Generation Capital Management LLC purchased a new stake in shares of Amarin during the fourth quarter worth about $50,000. Finally, Stonepine Capital Management LLC purchased a new position in Amarin during the 4th quarter valued at approximately $55,000. 22.25% of the stock is owned by institutional investors.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.